chlorhexidine
Trade name: hibitane
Approved
Jun 1, 1954
Chlorhexidine is a broad-spectrum biocide effective against Gram-positive bacteria, Gram-negative bacteria and fungi. It is used primarily as its salts (e.g., the dihydrochloride, diacetate, and digluconate). Chlorhexidine inactivates microorganisms with a broader spectrum than other antimicrobials (e.g. antibiotics) and has a quicker kill rate than other antimicrobials (e.g. povidone-iodine). It has both bacteriostatic (inhibits bacterial growth) and bactericidal (kills bacteria) mechanisms of action, depending on its concentration. Chlorhexidine kills by disrupting the cell membrane. The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; 4) toothache; 5) upper respiratory tract infection; and 6) headache. — NCATS
Clinical trial activity
565 trials · 460 clinical orgs · 30 marketing orgs
Earliest trial started May 1, 1998 (NCT00004640)
Timeline
1950s
- Jun 1, 1954
Imperial Chemical Industries — Earliest FDA Approval
- Jun 1, 1954
Imperial Chemical Industries — NDA Organization
1970s
- Sep 17, 1976
Molnlycke Health Care AB — NDA Secondary Org
1980s
- Dec 24, 1984
Xttrium Laboratories — NDA Secondary Org
- Jul 22, 1986
Ecolab — NDA Secondary Org
- Jul 24, 1986
Matrix Pharmaceutical — Marketing Organization
- Aug 13, 1986
3M — NDA Secondary Org
- Dec 17, 1987
Soapco — Marketing Organization
- Dec 2, 1988
CareFusion — NDA Secondary Org
- Mar 31, 1989
K. W. GRIFFEN CO — NDA Secondary Org
1990s
- Feb 28, 1991
Johnson and Johnson — Marketing Organization
- Jan 14, 1994
Colgate Palmolive — Marketing Organization
- Dec 15, 1995
Teva — Marketing Organization
- Dec 15, 1995
Pharmaceutical Associates — Marketing Organization
- Dec 28, 1995
Lyne Laboratories — Marketing Organization
- May 7, 1996
Saptalis Pharmaceuticals — Marketing Organization
- May 7, 1996
Hi Tech Pharmaceuticals — Marketing Organization
- May 7, 1996
Akorn, Inc. — Marketing Organization
- May 7, 1996
Sciegen Pharmaceticals — Marketing Organization
- Sep 11, 1997
Department of Veteran Affairs — NDA Secondary Org
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
- May 15, 1998
Dexcel Pharma Technologies Ltd. — NDA Secondary Org
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
- Jul 14, 2000
Becton Dickinson — Marketing Organization
- Jul 14, 2000
Becton Dickinson — NDA Secondary Org
- Nov 14, 2000
Department of Veteran Affairs — Marketing Organization
- Mar 3, 2004
Wockhardt — Marketing Organization
- Mar 3, 2004
Chartwell Pharmaceuticals — Marketing Organization
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
- Apr 25, 2005
Sage Products, Inc. — NDA Secondary Org
- Jun 3, 2005
PDI Healthcare — Marketing Organization
- Jun 3, 2005
PDI Healthcare — NDA Secondary Org
- Nov 29, 2005
Sunstar — Marketing Organization
- Jun 18, 2009
Xttrium Laboratories — Marketing Organization
- Jun 18, 2009
PHARMOBEDIENT — Marketing Organization
2010s
- Aug 8, 2018
Bausch Health Companies — NDA Secondary Org
- Nov 20, 2018
Medline Industries — NDA Secondary Org
Indications
Studied for
- Abscess · Phase 4
- Acanthamoeba Keratitis · Phase 3
- Acne Vulgaris · Phase 3
- Aggressive Periodontitis · Phase 4
- Allergy and Immunology · Phase 1
- Alveolar Bone Loss · Phase 1/Phase 2
- Alveolitis, Extrinsic Allergic · Phase 4
- Amputation, Surgical · Phase 4
- Anaplasia · Phase 3
- Anesthesia · Phase 3
- Ankle · Phase 4
- Antisepsis · Phase 4
- Arrhythmias, Cardiac · Phase 4
- Arthroplasty · Phase 4
- Arthroplasty, Replacement, Hip · Phase 4
- Arthroplasty, Replacement, Knee · Phase 4
- Asymptomatic Infections · Phase 4
- Bacteremia · Phase 4
- Bacteria · Phase 4
- Bacterial Infections · Phase 4
- Bacteriuria · Phase 4
- Biofilms · Phase 4
- Blood Pressure · Phase 4
- Breast Neoplasms · Phase 4
- Burns · Phase 2
- Candidiasis, Vulvovaginal · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Cardiovascular Diseases · Phase 4
- Cariostatic Agents · Phase 2/Phase 3
- Catheterization · Phase 2/Phase 3
- Catheter-Related Infections · Phase 4
- Catheters · Phase 4
- Cesarean Section · Phase 4
- Chemical Actions and Uses · Early Phase 1
- Chlorhexidine · Phase 4
- Chronic Periodontitis · Phase 3
- Clostridioides difficile · Phase 4
- Clostridium Infections · Phase 1
- Colonic Diseases · Phase 4
- Colonic Neoplasms · Phase 4
- Communicable Diseases · Phase 3
- Coronary Artery Disease · Phase 3
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 4
- Cross Infection · Phase 4
- Cystic Fibrosis · Phase 2
- Deglutition Disorders · Phase 3
- Dental Caries · Phase 4
- Dental Implantation · Early Phase 1
- Dental Implants · Phase 4
- Dental Plaque · Phase 4
- Dental Pulp Necrosis · Phase 2
- Dentist-Patient Relations · Phase 1
- Dermatology · Phase 4
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Angiopathies · Early Phase 1
- Diabetic Foot · Phase 4
- Disinfection · Early Phase 1
- Drug Delivery Systems · Phase 1/Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 2/Phase 3
- Drugs, Investigational · Phase 4
- Dry Socket · Phase 4
- Endodontics · Phase 2/Phase 3
- Erectile Dysfunction · Phase 3
- Esophageal Neoplasms · Phase 2/Phase 3
- Exanthema · Phase 1
- Foot Dermatoses · Phase 4
- Fractures, Bone · Phase 4
- Frail Elderly · Phase 4
- Frailty · Phase 1/Phase 2
- Gastrointestinal Microbiome · Phase 4
- Gels · Phase 4
- General Surgery · Phase 4
- Gingival Diseases · Phase 4
- Gingival Recession · Phase 4
- Gingivitis · Phase 4
- Halitosis · Phase 3
- Hamartoma · Phase 4
- Hand Hygiene · Phase 4
- Hand Injuries · Phase 4
- Head and Neck Neoplasms · Phase 2
- Healthcare-Associated Pneumonia · Phase 4
- Healthy Volunteers · Phase 4
- Heart Diseases · Phase 1
- Heart Failure · Phase 4
- Heart Failure, Diastolic · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 3
- Hemorrhage · Phase 3
- Hemorrhoids · Phase 2
- HIV Infections · Phase 2
- Hypertension, Pulmonary · Phase 1
- Hypochlorous Acid · Phase 2
- Hysterectomy · Phase 4
- Immune System Diseases · Phase 1/Phase 2
- Infant Mortality · Phase 3
- Infant, Newborn, Diseases · Phase 3
- Infant, Premature · Phase 2
- Infections · Phase 4
- Inflammation · Phase 4
- Keratitis · Phase 3
- Kidney Failure, Chronic · Phase 4
- Laparotomy · Phase 3
- Leg Ulcer · Phase 4
- Leukemia, Myeloid · Phase 3
- Leukemia, Myeloid, Acute · Phase 3
- Liver Neoplasms · Phase 4
- Long Term Adverse Effects · Phase 1/Phase 2
- Lung Neoplasms · Phase 2/Phase 3
- Macular Degeneration · Early Phase 1
- Malocclusion · Phase 3
- Methicillin-Resistant Staphylococcus aureus · Phase 4
- Microbiota · Phase 4
- Molar, Third · Phase 4
- Mouth · Phase 4
- Mouth Diseases · Phase 3
- Mouth Neoplasms · Phase 2
- Mouthwashes · Phase 2/Phase 3
- Mucositis · Phase 4
- Muscle, Skeletal · Phase 2/Phase 3
- Myelodysplastic Syndromes · Phase 2/Phase 3
- Neonatal Sepsis · Phase 2/Phase 3
- Neonatology · Phase 2/Phase 3
- Neoplasms · Phase 3
- Neutropenia · Phase 3
- Nicotine · Phase 1
- Nursing Homes · Phase 4
- Obesity · Phase 4
- Obesity, Morbid · Phase 4
- Opioid-Related Disorders · Phase 4
- Oral Health · Phase 4
- Oral Hygiene · Phase 4
- Oral Manifestations · Phase 2
- Oral Ulcer · Phase 4
- Orbit · Phase 4
- Oropharyngeal Neoplasms · Phase 2
- Osteoarthritis · Phase 2
- Osteonecrosis · Phase 4
- Pain · Phase 3
- Pancreatitis, Acute Necrotizing · Phase 4
- Pathologic Processes · Phase 3
- Penile Diseases · Phase 2
- Penile Prosthesis · Phase 3
- Periapical Abscess · Phase 2/Phase 3
- Periapical Periodontitis · Phase 3
- Peri-Implantitis · Phase 4
- Periodontal Diseases · Phase 4
- Periodontal Index · Phase 3
- Periodontal Pocket · Phase 3
- Periodontitis · Phase 4
- Peritoneal Dialysis · Phase 4
- Personal Satisfaction · Phase 4
- Pharmacology · Phase 4
- Pharyngitis · Phase 4
- Pneumonia · Phase 4
- Pneumonia, Aspiration · Phase 4
- Pneumonia, Ventilator-Associated · Phase 4
- Postoperative Complications · Phase 4
- Postoperative Nausea and Vomiting · Phase 4
- Postpartum Period · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Pregnant People · Phase 4
- Propionibacterium acnes · Phase 4
- Prostheses and Implants · Phase 1/Phase 2
- Prosthesis-Related Infections · Phase 3
- Pseudomonas aeruginosa · Phase 4
- Psychological Distress · Phase 2
- Puerperal Infection · Phase 3
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Pulpitis · Phase 3
- Quality of Life · Phase 4
- Radiodermatitis · Phase 2/Phase 3
- Respiratory Tract Infections · Phase 3
- Retinal Diseases · Early Phase 1
- Saliva · Phase 2/Phase 3
- Sarcoma · Phase 2
- Sepsis · Phase 4
- Skin Diseases, Infectious · Phase 4
- Soft Tissue Infections · Phase 4
- Spinal Injuries · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Staphylococcal Infections · Phase 4
- Staphylococcus aureus · Phase 4
- Stomatitis · Phase 4
- Stomatognathic Diseases · Early Phase 1
- Substance Abuse, Oral · Phase 4
- Surgery, Oral · Phase 4
- Surgical Wound Infection · Phase 4
- Sutures · Phase 4
- Toes · Phase 4
- Tooth Abnormalities · Phase 4
- Tooth Loss · Phase 3
- Tooth Socket · Phase 4
- Ultrasonography · Phase 4
- Umbilical Cord · Phase 3
- Urinary Tract Infections · Phase 4
- Vagina · Phase 4
- Ventilators, Mechanical · Phase 4
- Vitreoretinopathy, Proliferative · Early Phase 1
- Wound Healing · Phase 3
- Wound Infection · Phase 4
- Wounds and Injuries · Phase 4
Mechanism of action
- Cell membraneINHIBITOR
Cell membrane inhibitor
Disrupts cell membrane
Combination products
avagar
with ethanol
chloraprep one-step
with isopropyl alcohol
Also known as chloraprep one-step frepp, chloraprep one-step sepp, chloraprep single swabstick, chloraprep triple swabstick, chloraprep with tint, prevantics maxi swabstick, prevantics swab, prevantics swabstick
Approval history
- approvedJun 1, 1954
Chemistry & pharmacology
SMILES
ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1- Mol. weight
- 505.447 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaChlorhexidine ↗
- NCATSR4KO0DY52L ↗
- ChEMBLCHEMBL4297088 ↗
- ChEMBLCHEMBL790 ↗
- ChEMBLCHEMBL1484251 ↗
- ChEMBLCHEMBL1628 ↗
- ChEMBLCHEMBL486819 ↗
Also known as
- 1,1'-hbcb
- 1,1'-hexamethylenebis-(5-(ethylhexyl)biguanide)
- 1,1'-hexamethylene bis(5-(p-chlorophenyl)biguanide)
- 1,1'-hexamethylene bis(5-(p-chlorophenyl)biguanide)
- acriflex
- aerocide 1
- alcoholic chlorhexidine
- avagard
- avagard
- avagard
- bacticlens
- bioscrub
- bioscrub
- brian care
- brian care
- cepton
- cetriclens
- cetriclens fte
- chg scrub
- chlohexidine gluconate
- chlohexidine gluconate
- chloraprep
- chloraprep
- chlorexidine
- chlorhexamed
- chlorhex glucon
- chlorhex hcl
- chlorhexidin
- chlorhexidin
- chlorhexidine
- chlorhexidine
- chlorhexidine
- chlorhexidine
- chlorhexidine
- chlorhexidine
- chlorhexidine
- chlorhexidine
- chlorhexidine acetate
- chlorhexidine acetate
- chlorhexidine bigluconate
- chlorhexidine digluconate
- chlorhexidine digluconate
- chlorhexidine digluconate
- chlorhexidine gluconate
- chlorhexidine gluconate
- chlorhexidine gluconate
- chlorhexidine gluconate
- chlorhexidine gluconate
- chlorhexidine gluconate
- chlorhexidine gluconate mixture with isopropyl alcohol
- chlorhexidine hcl
- chlorhexidine hcl
- chlorhexidine hydrochloride
- chlorhexidine hydrochloride
- chlorhexidine hydrochloride
- chlorhexidine hydrochloride
- chlorhexidine hydrochloride
- chlorhexidine hydrochloride
- chlorhexidinum
- chlorhexidinum
- chlorohex
- chlorohexidine
- chlorohexidine
- chlorohexidine
- chlorohexidine gluconate
- cida-stat
- cida-stat
- clinivex
- cloresidina
- cloresidina
- clorhexidina
- clorhexidina
- clorhexidine
- corsodyl
- corsodyl
- corsodyl daily
- corsodyl daily defence
- corsodyl ici
- curasept
- curasept
- curasept ads 220
- cx 1
- cyteal
- dispray 1
- dispray 2
- dyna-hex
- dyna-hex
- dyna-hex
- eczmol
- eludril
- exidine
- exidine
- e-z scrub
- gibitan
- gppe soln
- gppe tinct
- gppe wsh
- habitant
- hexidine
- hibclens
- hibi
- hibicet
- hibiclens
- hibiclens
- hibiclens
- hibident
- hibidil
- hibidil
- hibiscrub
- hibiscrub
- hibiscrub
- hibisol
- hibispray
- hibispray
- hibistat
- hibistat
- hibitane
- hibitane plus
- hydrex
- microderm
- microderm
- n,n'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
- n,n'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
- peridex
- peridex
- peridex
- periochip
- periochip
- perio chip
- periogard
- periogard
- perio-kin
- pharmaseal scrub care
- pharmaseal scrub care
- phiso-med
- phiso-med
- prevacare
- prevacare
- prevacare r
- prevacare r
- primahex
- rotersept
- rotersept
- rotersept
- savloclens
- savloclens
- savlodil
- savlon hc
- savlon jnr
- sterets tisept
- sterets uniscrub
- sterets unisept
- sterexidine
- steri-stat
- steri-stat
- tarodent
- tisept
- uriflex-c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07200063 | N/A | Jan 31, 2026 | Cairo University |
| NCT07311512 | N/A | Jan 23, 2026 | Imperial College London, Loughborough University, Temple University, University of Portsmouth |
| NCT07191262 | N/A | Dec 31, 2025 | University of Alabama, Birmingham |
| NCT07239219 | N/A | Dec 31, 2025 | Irrimax Corporation, Ohio State University |
| NCT07307716 | N/A | Dec 31, 2025 | Riyadh Elm University |
| NCT07215156 | N/A | Oct 6, 2025 | Kafrelsheikh University |
| NCT07196618 | N/A | Sep 30, 2025 | Al Azhar University |
| NCT07124650 | Phase 4 | Sep 15, 2025 | Saint-Petersburg State Medical University |
| NCT07016659 | Phase 3 | Sep 1, 2025 | Cairo University |
| NCT07058727 | N/A | Aug 1, 2025 | Cukurova University |
| NCT07119840 | N/A | Aug 1, 2025 | Khyber Medical University Peshawar, Khyber Medical University Peshawer, Saidu College of Dentistry |
| NCT07069166 | N/A | Jul 30, 2025 | University of Pavia |
| NCT07115784 | N/A | Jul 21, 2025 | Khyber Medical University Peshawar |
| NCT07252258 | N/A | Jul 15, 2025 | College of Physicians and Surgeons Pakistan |
| NCT07073092 | Phase 2 | Jul 15, 2025 | Ain Shams University |
| NCT07031388 | N/A | Jul 1, 2025 | Kurdistan Board for Medical Specialist |
| NCT07059572 | N/A | May 27, 2025 | Bangladesh Medical University |
| NCT07198919 | Phase 1/Phase 2 (Phase 2) | May 20, 2025 | Altamash Institute of Dental Medicine |
| NCT07180498 | N/A | Apr 15, 2025 | Harran University |
| NCT06900881 | Phase 2/Phase 3 (Phase 3) | Apr 6, 2025 | Al-Mustansiriyah University |
Organizations
Research & Development (460)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cairo University | Academic/Hospital | 27 | 27 | 5 | 2016 |
| 3M | For profit | 14 | 11 | 4 | 2007 |
| Johns Hopkins University | Academic/Hospital | 12 | 11 | 4 | 2004 |
| Bio-Science Laboratories | For profit | 9 | 0 | 4 | 2013 |
| Medline Industries | For profit | 9 | 9 | 3 | 2014 |
| University of Pavia | Academic/Hospital | 9 | 9 | 1 | 2021 |
| Zurex Pharma, Inc. | For profit | 9 | 9 | 3 | 2014 |
| Centers for Disease Control and Prevention (CDC) | Government | 8 | 1 | 4 | 2004 |
| Colgate Palmolive | For profit | 8 | 5 | 3 | 1998 |
| University of Milan | Academic/Hospital | 8 | 8 | 3 | 2011 |
| Washington University in St. Louis | Academic/Hospital | 8 | 5 | 4 | 2007 |
| Department of Veteran Affairs | Government | 7 | 4 | 4 | 2001 |
| National Institute of Dental and Craniofacial Research (NIDCR) | Government | 7 | 0 | 4 | 1998 |
| Sage Products, Inc. | For profit | 7 | 0 | 3 | 2005 |
| University of Santiago de Compostela | Academic/Hospital | 7 | 7 | 3 | 2010 |
| Ain Shams University | Academic/Hospital | 6 | 6 | 3 | 2014 |
| CareFusion | For profit | 6 | 5 | 3 | 2007 |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | Academic/Hospital | 6 | 0 | 3 | 2005 |
| MicroBioTest | For profit | 6 | 0 | 3 | 2011 |
| Rush University | Academic/Hospital | 6 | 3 | 4 | 2005 |
Marketing (37)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| 3M | For profit | NDA2 | Aug 13, 1986 |
| 3M | For profit | SYN | Aug 8, 2018 |
| Akorn, Inc. | For profit | MKTG | May 7, 1996 |
| Bausch Health Companies | For profit | NDA2 | Aug 8, 2018 |
| Becton Dickinson | For profit | SYN | Oct 24, 1989 |
| Becton Dickinson | For profit | MKTG | Jul 14, 2000 |
| Becton Dickinson | For profit | NDA2 | Jul 14, 2000 |
| CareFusion | For profit | NDA2 | Dec 2, 1988 |
| Chartwell Pharmaceuticals | For profit | MKTG | Mar 3, 2004 |
| Colgate Palmolive | For profit | MKTG | Jan 14, 1994 |
| Colgate Palmolive | For profit | SYN | Jan 28, 2016 |
| Department of Veteran Affairs | Government | MKTG | Nov 14, 2000 |
| Department of Veteran Affairs | Government | NDA2 | Sep 11, 1997 |
| Dexcel Pharma Technologies Ltd. | For profit | NDA2 | May 15, 1998 |
| Ecolab | For profit | NDA2 | Jul 22, 1986 |
| Hi Tech Pharmaceuticals | For profit | MKTG | May 7, 1996 |
| Imperial Chemical Industries | For profit | NDA | Jun 1, 1954 |
| Johnson and Johnson | For profit | MKTG | Feb 28, 1991 |
| K. W. GRIFFEN CO | For profit | NDA2 | Mar 31, 1989 |
| Kendall McGaw Laboratories | For profit | NDA2 | — |
| Lyne Laboratories | For profit | MKTG | Dec 28, 1995 |
| Matrix Pharmaceutical | For profit | MKTG | Jul 24, 1986 |
| Medline Industries | For profit | NDA2 | Nov 20, 2018 |
| Molnlycke Health Care AB | For profit | NDA2 | Sep 17, 1976 |
| PDI Healthcare | For profit | MKTG | Jun 3, 2005 |
| PDI Healthcare | For profit | NDA2 | Jun 3, 2005 |
| PHARMOBEDIENT | For profit | MKTG | Jun 18, 2009 |
| Pharmaceutical Associates | For profit | MKTG | Dec 15, 1995 |
| Sage Products, Inc. | For profit | NDA2 | Apr 25, 2005 |
| Saptalis Pharmaceuticals | For profit | MKTG | May 7, 1996 |
| Sciegen Pharmaceticals | For profit | MKTG | May 7, 1996 |
| Soapco | Academic/Hospital | MKTG | Dec 17, 1987 |
| Sunstar | For profit | MKTG | Nov 29, 2005 |
| Teva | For profit | MKTG | Dec 15, 1995 |
| Wockhardt | For profit | MKTG | Mar 3, 2004 |
| Xttrium Laboratories | For profit | NDA2 | Dec 24, 1984 |
| Xttrium Laboratories | For profit | MKTG | Jun 18, 2009 |